Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado
ENGLEWOOD, Colo., July 23 2014 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the opening of its new headquarters, manufacturing and research facility:
373 Inverness Parkway
Englewood, CO 80112
Direct: (720) 437-6500
Michael Macaluso, Ampio’s CEO, noted “This advanced, labor efficient, pharmaceutical drug manufacturing facility will be fully operational this summer, right on schedule, to produce the first batches of Ampion(TM) necessary to accommodate the company’s BLA application to treat osteoarthritis-of-the- knee (OAK). This factory is designed to manufacture and package 10 million doses per year of Ampion(TM) as an injectable drug for the treatment of osteoarthritis as well as for additional formulations of Ampion(TM) to treat other clinical indications. This factory will be fully compliant with regulatory requirements for both the USA and international medical manufacturing. Also located in this facility are State-of-the-art molecular biology and analytical research laboratories.”
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
Forward Looking Statements
Ampio’s statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s expectations with respect to the completion, timing and size of the registered direct offering, as well as risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6500
SOURCE Ampio Pharmaceuticals, Inc.